BioCardia Inc
NASDAQ:BCDA
Intrinsic Value
BioCardia, Inc. operates as a clinical-stage regenerative medicine company. [ Read More ]
The intrinsic value of one BCDA stock under the Base Case scenario is 2.763 USD. Compared to the current market price of 0.368 USD, BioCardia Inc is Undervalued by 87%.
Valuation Backtest
BioCardia Inc
Run backtest to discover the historical profit from buying and selling BCDA stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
BioCardia Inc
Current Assets | 1.5m |
Cash & Short-Term Investments | 1.1m |
Receivables | 63k |
Other Current Assets | 295k |
Non-Current Assets | 1.5m |
PP&E | 1.4m |
Other Non-Current Assets | 171k |
Current Liabilities | 3.6m |
Accounts Payable | 890k |
Accrued Liabilities | 2.1m |
Other Current Liabilities | 632k |
Non-Current Liabilities | 982k |
Other Non-Current Liabilities | 982k |
Earnings Waterfall
BioCardia Inc
Revenue
|
477k
USD
|
Operating Expenses
|
-12.1m
USD
|
Operating Income
|
-11.6m
USD
|
Other Expenses
|
73k
USD
|
Net Income
|
-11.6m
USD
|
Free Cash Flow Analysis
BioCardia Inc
BCDA Profitability Score
Profitability Due Diligence
BioCardia Inc's profitability score is 25/100. The higher the profitability score, the more profitable the company is.
Score
BioCardia Inc's profitability score is 25/100. The higher the profitability score, the more profitable the company is.
BCDA Solvency Score
Solvency Due Diligence
BioCardia Inc's solvency score is 40/100. The higher the solvency score, the more solvent the company is.
Score
BioCardia Inc's solvency score is 40/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BCDA Price Targets Summary
BioCardia Inc
Ownership
BCDA Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
BCDA Price
BioCardia Inc
Average Annual Return | -26.4% |
Standard Deviation of Annual Returns | 31.75% |
Max Drawdown | -98% |
Market Capitalization | 9.8m USD |
Shares Outstanding | 26 732 500 |
Percentage of Shares Shorted | 2.33% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
BioCardia, Inc. operates as a clinical-stage regenerative medicine company. The company is headquartered in Sunnyvale, California and currently employs 28 full-time employees. The company is focused on developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases. Its lead therapeutic candidates are based on the CardiAMP Cell Therapy System, a platform which provides an autologous bone marrow-derived cell therapy for treatment in two clinical indications, such as ischemic heart failure and refractory angina resulting from chronic myocardial ischemia. Its second therapeutic platform is an investigational bone marrow derived allogeneic off-the shelf Neurokinin-1 Receptor Positive mesenchymal stem cell (MSC) therapy for the treatment of cardiac and pulmonary disease. The company has three enabling device product lines: the CardiAMP cell processing system, the Helix biotherapeutic delivery system (Helix), and the Morph vascular access product line (Morph). The company is advancing therapeutic candidates for heart failure, chronic myocardial infarction, and acute respiratory distress syndrome.
Contact
IPO
Employees
Officers
The intrinsic value of one BCDA stock under the Base Case scenario is 2.763 USD.
Compared to the current market price of 0.368 USD, BioCardia Inc is Undervalued by 87%.